Ryvu Therapeutics Balans Gezondheid
Financiële gezondheid criteriumcontroles 5/6
Ryvu Therapeutics has a total shareholder equity of PLN205.4M and total debt of PLN60.5M, which brings its debt-to-equity ratio to 29.5%. Its total assets and total liabilities are PLN406.6M and PLN201.2M respectively.
Belangrijke informatie
29.5%
Verhouding schuld/eigen vermogen
zł60.51m
Schuld
| Rente dekkingsratio | n/a |
| Contant | zł254.20m |
| Aandelen | zł205.41m |
| Totaal verplichtingen | zł201.24m |
| Totaal activa | zł406.65m |
Recente financiële gezondheidsupdates
Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt
Oct 20
We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate
Aug 02Recent updates
Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt
Oct 20We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate
Aug 02Are Investors Undervaluing Ryvu Therapeutics S.A. (WSE:RVU) By 20%?
Jan 25What Type Of Shareholders Own The Most Number of Ryvu Therapeutics S.A. (WSE:RVU) Shares?
Feb 05Shareholders Of Ryvu Therapeutics (WSE:RVU) Must Be Happy With Their 261% Total Return
Dec 14Analyse van de financiële positie
Kortlopende schulden: RVU's short term assets (PLN296.5M) exceed its short term liabilities (PLN89.2M).
Langlopende schulden: RVU's short term assets (PLN296.5M) exceed its long term liabilities (PLN112.0M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: RVU has more cash than its total debt.
Schuld verminderen: RVU's debt to equity ratio has increased from 2.1% to 29.5% over the past 5 years.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: RVU has sufficient cash runway for more than a year based on its current free cash flow.
Voorspelling contante baan: RVU has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 5.5% each year.